Mutual of America Capital Management LLC Raises Position in STAAR Surgical (NASDAQ:STAA)

Mutual of America Capital Management LLC increased its position in shares of STAAR Surgical (NASDAQ:STAA) by 214.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,459 shares of the medical instruments supplier’s stock after purchasing an additional 18,051 shares during the period. Mutual of America Capital Management LLC’s holdings in STAAR Surgical were worth $1,260,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in STAA. GAMMA Investing LLC raised its stake in shares of STAAR Surgical by 313.9% during the 1st quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 992 shares in the last quarter. Covestor Ltd lifted its holdings in STAAR Surgical by 38.9% in the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock valued at $103,000 after acquiring an additional 754 shares during the period. Larson Financial Group LLC purchased a new stake in shares of STAAR Surgical during the 2nd quarter worth $130,000. Virtu Financial LLC purchased a new stake in shares of STAAR Surgical during the 1st quarter worth $289,000. Finally, Sierra Summit Advisors LLC acquired a new position in shares of STAAR Surgical during the 4th quarter worth $323,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on STAA shares. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, September 19th. Morgan Stanley lowered STAAR Surgical from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $50.00 to $37.00 in a research note on Monday, July 15th. Stifel Nicolaus dropped their price objective on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, August 26th. Canaccord Genuity Group decreased their target price on STAAR Surgical from $43.00 to $41.00 and set a “hold” rating on the stock in a research report on Thursday, August 8th. Finally, BTIG Research raised their price target on STAAR Surgical from $46.00 to $53.00 and gave the company a “buy” rating in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $45.57.

Insider Activity

In other news, Director Arthur C. Butcher acquired 1,315 shares of STAAR Surgical stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average price of $37.99 per share, with a total value of $49,956.85. Following the completion of the purchase, the director now owns 4,208 shares of the company’s stock, valued at approximately $159,861.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.00% of the company’s stock.

STAAR Surgical Stock Up 9.1 %

NASDAQ STAA opened at $33.87 on Friday. STAAR Surgical has a fifty-two week low of $26.66 and a fifty-two week high of $52.68. The business has a fifty day moving average of $35.24 and a 200-day moving average of $40.29. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of 109.26 and a beta of 0.58.

STAAR Surgical (NASDAQ:STAA) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.09). The firm had revenue of $99.01 million during the quarter, compared to analyst estimates of $95.22 million. STAAR Surgical had a net margin of 4.99% and a return on equity of 5.60%. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.23 EPS. As a group, analysts anticipate that STAAR Surgical will post 0.17 EPS for the current year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.